ETCTN Early Drug Development Opportunity Leadership program administrative supplement to Cancer Center Support Grant

ETCTN 早期药物开发机会领导计划对癌症中心支持补助金的行政补充

• 批准号: 10363981
• 负责人: GEROLD BEPLER
• 金额: $ 12.5万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10363981
• 关键词: Administrative Supplement; African American; Area; Basic Science; Biopsy; CD8-Positive T-Lymphocytes; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Patient; Catchment Area; Cells; Censuses; Cities; Clinic; Clinical Research; Clinical Trials; Compassion; Comprehensive Cancer Center; County; Education; Failure; Grant; Healthcare; Home; Household; Income; Institutes; Intervention; Leadership; Location; Malignant Neoplasms; Measures; Medically Underserved Area; Michigan; Minority; Minority Groups; Mission; Molecular; Molecular Profiling; Myeloid-derived suppressor cells; Neuroendocrine Carcinoma; Nivolumab; Parents; Patient Care; Patients; Physicians; Population; Population Research; Population Study; Poverty; Prior Therapy; Progression-Free Survivals; Quality of Care; Research; Research Institute; Resource Sharing; Resources; Safety; Therapeutic; Therapeutic Studies; Translational Research; Treatment Protocols; Treatment outcome; Tumor Biology; Tumor-associated macrophages; Tumor-infiltrating immune cells; U-Series Cooperative Agreements; United States Health Resources and Services Administration; United States National Institutes of Health; Universities; anticancer research; base; cancer care; disorder control; drug development; exome sequencing; ipilimumab; member; metropolitan; molecular imaging; neoplastic cell; neuroendocrine differentiation; operation; programmed cell death ligand 1; programs; response; social disparities; suburb; success; transcriptome sequencing; tumor; tumor microenvironment

This application is being submitted in response to the EDDOP Leadership Program via the mechanism PA-20- 272, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).” The Karmanos Cancer Institute (KCI), founded in 1943, is a not-for-profit, cancer-only research and patient care organization in partnership with Wayne State University (WSU) in Michigan. The designation by the NCI as a Comprehensive Cancer Center was achieved in 1978. KCI operates its wholly-owned, free-standing, cancer hospital and ambulatory clinics (KCC) in Detroit and in Farmington Hills, a suburban location. As a member of McLaren Health Care (MHC), a not-for profit health care corporation, KCI is also responsible for cancer research, quality of care, and cancer care operations in all facilities owned and operated by MHC. Our catchment area covers 46 of Michigan's 83 counties with a population of 6.7 million people. This catchment area is home to 95% of our patients, and KCI sees one-third of all new cancer patients in the catchment area. The Southeast region of our catchment area includes the metropolitan Detroit, defined as a tri-county area (Wayne, Oakland, Macomb) and home to 3.86 million residents. The city of Detroit is the largest city in the state (672,000 residents). Detroit is a resource-challenged area, with a median household income of $27,838 and 37.9% of residents living below poverty level, compared to 16.7% in the state of Michigan. The majority of census tracts in the city of Detroit are medically underserved areas based on HRSA definitions. About 79% of Detroit residents identify as African American, a group that disproportionately carries KCI catchment area's cancer burden. In 2018, KCI physicians saw approximately 12,000 new cancer patients (including approximately 8,000 analytic cases), with approximately 15% representing minority groups. The annual number of new cancer cases in these 46 counties is approximately 39,000 and has not changed significantly since 2014. In FY19, our minority accrual to interventional treatment protocols was 24.2%. We have a long standing scientific and patient care commitment to the African American population of southeastern Michigan, as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This application profiles the strengths and successes of our four scientific Programs, Tumor Biology and Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population Studies and Disparities Research (PSDR, 04). The research efforts of these Programs is supported by nine Shared Resources (Cores), including one developing Core.

本申请是通过PA-20机制提交的，以响应EDDOP领导计划， 272，“对现有NIH赠款和合作协议的行政补充（家长行政补充 临床试验可选）。 Karmanos癌症研究所（KCI）成立于1943年，是一家非营利性的癌症研究和患者治疗机构。 护理组织与密歇根州的韦恩州立大学（WSU）合作。国家癌症研究所指定的 1978年建成了综合癌症中心。KCI经营其全资拥有的，独立的， 底特律和郊区法明顿山的癌症医院和门诊诊所（KCC）。作为 McLaren Health Care（MHC）是一家非营利性医疗保健公司，KCI还负责 癌症研究，护理质量，以及MHC拥有和经营的所有设施中的癌症护理操作。我们 集水区覆盖密歇根州83个县中的46个，人口670万。这个集 该地区是我们95%的患者的家园，KCI在集水区看到了所有新癌症患者的三分之一。 我们的集水区的东南部地区包括底特律大都市，定义为三县区 （韦恩，奥克兰，马科姆）和386万居民的家园。底特律市是美国最大的城市， 州（672，000居民）。底特律是一个资源短缺的地区，家庭收入中位数为27，838美元 37.9%的居民生活在贫困线以下，而密歇根州为16.7%。大多数 根据HRSA的定义，底特律市的人口普查区是医疗服务不足的地区。约79%的 底特律居民认为是非洲裔美国人，这是一个不成比例地携带KCI集水区的群体。 癌症负担在2018年，KCI医生看到了大约12，000名新的癌症患者（包括 约8，000个分析案例），其中约15%代表少数群体。年度 这46个县的新癌症病例数约为39，000例，没有显著变化 自2014年起在2019财年，我们的少数参与介入治疗方案的比例为24.2%。我们还有很长的 对密歇根州东南部非洲裔美国人的长期科学和病人护理承诺， 这一点可以从一系列广泛的研究中得到证明，这些研究集中在分子、治疗和社会差异方面。这 应用程序简介我们的四个科学计划，肿瘤生物学和 微环境（TBM，01），分子成像（MI，02），分子治疗（MT，03）和人口 研究与差异研究（PSDR，04）。这些项目的研究工作得到了九个国家的支持。 共享资源（核心），包括一个正在开发的核心。